Martin Shkreli . . . whistleblower? The Federal Trade Commission is preparing to file charges against Irish drugmaker Mallinckrodt for allegedly using its monopoly to jack up the price of a drug used to treat lupus and multiple sclerosis by 2,165 percent, to $28,000 a dose, The Post has learned. The FTC has been investigating...
read more
Source: New York Post